Page last updated: 2024-08-23

pirfenidone and pai 039

pirfenidone has been researched along with pai 039 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Didiasova, M; Drakopanagiotakis, F; Krämer, M; Mamazhakypov, A; Markart, P; Schaefer, L; Wygrecka, M	1

Other Studies

1 other study(ies) available for pirfenidone and pai 039

Article	Year
Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. Cellular signalling, 2020, Volume: 65 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Indoleacetic Acids; Lung Neoplasms; Membrane Proteins; Plasminogen Activator Inhibitor 1; Pyridones; Tumor Microenvironment; Urokinase-Type Plasminogen Activator	2020

Article

Year

Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.

Cellular signalling, 2020, Volume: 65

Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Indoleacetic Acids; Lung Neoplasms; Membrane Proteins; Plasminogen Activator Inhibitor 1; Pyridones; Tumor Microenvironment; Urokinase-Type Plasminogen Activator

2020